Debiopharm Group™ is a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs. It in-licenses promising biologics and small molecule candidates.
The group develops its products with a view to licensing them out to pharmaceutical partners for sales and marketing.
Debiopharm Group is financially independent.
A biopharmaceutical development company that in-licenses promising biologics and small molecule drug candidates for global development.
Applied research, drug delivery systems, FDA and SwissMedic inspected production facility. More info
Financing of biotechnology and pharmaceutical start-ups to create synergies with Debiopharm Group. More info
The financial arm of Debiopharm Group. Debiomanagement comprises a Financial Department, a Real Estate Department and a Private Equity Department. More info
Debiopharm Group Strategic Committee
The Strategic Committee is a prospective think-tank advising the shareholders and the leadership of the group against the background of a changing environment. More info
Debiopharm Group Auditing Committee
The Auditing Committee monitors and enhances good administrative and management practices as well as risk control at group level. More info